Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

Wataru Fukuokaya, Yuhei Koike, Yuji Yata, Kazumasa Komura, Taizo Uchimoto, Takuya Tsujino, Masanobu Saruta, Kiyoshi Takahara, Kazutoshi Fujita, Takafumi Minami, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Yoshio Ohno, Hirotsugu Uemura, Ryoichi Shiroki, Haruhito Azuma, Takahiro Kimura

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Objectives: To explore the characteristics of patients and assess the effectiveness of enfortumab vedotin (EV) in those with treatment-resistant advanced urothelial cancer in a real-world setting. Patients and Methods: A multicenter observational study was conducted on 103 evaluable patients with advanced urothelial cancer who received EV. Outcomes were assessed by radiographic response, progression-free survival (PFS), and overall survival (OS), with treatment-related adverse events (trAEs). Radiographic response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1, while trAEs were studied in line with Common Terminology Criteria for Adverse Events version 5.0. Results: The median follow-up was 8.9 months (range, 0.1–16.4). The observed objective response rate was 50.5%. The median PFS was 6.0 months (95% CI: 4.7–9.8), and the median OS was 14.5 months (95% CI: 12.4–not reached). Out of the 103 patients, 19 (18.4%) had an Eastern Cooperative Oncology Group performance status of 2 or more, 14 (14.7%) had an non-urothelial carcinoma histology, and 40 (38.3%) had at least one pre-existing comorbidity. There were 26 (25.2%) patients who reported 49 trAEs, with 9 (18.3%) being grade 3 or higher. The most common trAEs included rash, occurring in 18.4%. Conclusions: This study describes the characteristics and outcomes of patients with previously treated advanced urothelial cancer receiving EV. The findings demonstrate that EV showed robust anti-tumor activity and had manageable safety profiles outside the clinical trial setting.

Original languageEnglish
Pages (from-to)342-347
Number of pages6
JournalInternational Journal of Urology
Volume31
Issue number4
DOIs
Publication statusPublished - 04-2024

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint

Dive into the research topics of 'Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study'. Together they form a unique fingerprint.

Cite this